Objective Chemoradiation-based neoadjuvant treatment followed by radical surgery is an alternative therapeutic strategy for locally advanced cervical cancer (LACC) PE (sensitivity, 47.9%; specificity, 84.2%); 7.8 s for tumor RT (sensitivity, 68.8%; specificity, 57.9%); and 4902 for tumor WiR (sensitivity, 77.1%; specificity, 60.5%) 
Methods Between October 2010 and June 2014, we screened 108 women with histologically documented LACC Stage IB2-IVA, of whom 88 were included in the final analysis. Tumor volume, three-dimensional (3D) power Doppler indices and contrast parameters were obtained before (baseline examination) and after 2 weeks of treatment. The pathological response was defined as complete (absence of any residual tumor after treatment) or partial (microscopic and/or macroscopic residual tumor at pathological examination).
Complete-response and partial-response groups were compared and receiver-operating characteristics (ROC) curves were generated for ultrasound variables that were statistically significant on univariate analysis to evaluate their diagnostic ability to predict partial pathological response.
Results

There was a complete pathological response to neoadjuvant therapy in 40 (45.5%) patients and a
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.5%). At baseline examination, tumor volume did not differ between the two groups. However, after 2 weeks of neoadjuvant treatment, the tumor volume was significantly greater in patients with partial response than it was in those with complete response (P = 0.019). Among the 3D vascular indices, the vascularization index (VI) was significantly lower in the partial-response compared with the complete-response group, both before and after 2 weeks of treatment (P =
0
INTRODUCTION
Cervical cancer is the second most common malignancy in women worldwide 1, 2 , and treatment depends mainly on tumor stage according to the Federation Internationale de Gynécologie et d' Obstétrique (International Federation of Gynaecology and Obstetrics, FIGO) 3 . Although FIGO recommends a clinical staging system for cervical cancer, it is well known that the accuracy of such a system is suboptimal and, while magnetic resonance imaging (MRI) has a well-established role in the evaluation of tumor extension 4 , transvaginal and transrectal ultrasound have been recognized only recently as feasible and accurate methods to evaluate local spread of cervical cancer [5] [6] [7] [8] , which is pivotal to deciding the correct treatment. Since 1999, chemoradiation therapy has been the standard treatment for locally advanced cervical cancer 9, 10 , but investigational approaches involving completion surgery after chemoradiation have shown encouraging results in terms of disease-free and overall survival [11] [12] [13] [14] , and chemoradiation followed by radical surgery has been found feasible and safe [15] [16] [17] [18] . Surgery also represents the only method to obtain reliably the most important prognostic information: pathological response to treatment. Patients achieving complete pathological response to neoadjuvant chemoradiation therapy have been found to experience a significantly better disease-free survival rate and longer overall survival than those with partial (microscopic or macroscopic) response 18 . One of the major criticisms of performing radical surgery after chemoradiation is the potentially higher risk of complications associated with radiation-induced tissue sequelae, such as inflammation, vascular fibrosis and firm adhesions. Toxicity is recognized as a common problem of any multimodal approach, and the frequency of complications after chemoradiation plus radical surgery (especially urinary and lymphatic ones) ranges from 9% to 26% for Grade-2 complications 12, [19] [20] [21] [22] . On the other hand, definitive chemoradiation with brachytherapy-related vaginal morbidity and associated sexual dysfunction is an important cause of long-term distress in cervical cancer survivors, with a high-grade vaginal stenosis risk of around 21% 23 . Thus, it would be useful to identify accurate and non-invasive methods that are able to distinguish promptly, both before and early in treatment, between those patients who will experience a partial and those who will experience a complete pathological response to neoadjuvant chemoradiation therapy.
There are few data in the literature assessing the role of ultrasound examination in the evaluation of tumor behavior during neoadjuvant treatment 24, 25 . The use of two-dimensional (2D) ultrasound and three-dimensional (3D) power Doppler, as well as contrast enhancement using SonoVue (sulphur hexafluoride microbubbles), has been investigated in cervical cancer 4, 5, 25, 26 , but their ability to predict pathological response in locally advanced cervical cancer has not yet been investigated.
We performed a prospective study (PRICE: PRospective Imaging of CErvical cancer and neoadjuvant treatment) aimed at analyzing the predictive ability of each of the most important diagnostic tools, including ultrasound, positron emission tomography/computed tomography (PET/CT) and MRI, and their complementary roles in patients with histologically documented locally advanced cervical cancer triaged to chemoradiation therapy followed by radical surgery. In the current study, we report the diagnostic performance of ultrasound parameters, including those obtained by means of 3D intravenous contrast-enhancement, in the early prediction of partial pathological response, assessed in terms of residual disease at histology, to neoadjuvant treatment followed by radical surgery in a large, single-institution series of locally advanced cervical cancer patients.
SUBJECTS AND METHODS
Study protocol
The original PRICE study protocol involved three assessment sessions for each patient, including transvaginal ultrasound examination, MRI and PET/CT scan, performed before treatment ('baseline' evaluation), after 2 weeks of neoadjuvant treatment ('early' evaluation) and 5 weeks after the end of treatment ('final' evaluation). The timing of evaluations was agreed by the radiotherapist, ultrasound examiner and radiologist 27 . For each session, the planned time interval between the three imaging modalities did not exceed 1 week. In the present study, we considered ultrasound data only, obtained at baseline and after 2 weeks of treatment, while the ultrasound data from the final evaluation 28 and the data for the other two diagnostic methods, MRI and PET/CT, will be presented in further papers, including only the best ultrasound variables identified by the present analysis.
Work-up and eligibility
Between October 2010 and June 2014, patients with histologically documented cervical cancer (any histology) and Stage IB2-IVA disease, according to FIGO classification 3 , were enrolled prospectively at the Gynecologic Oncology Unit of the Catholic University in Rome, Italy. Other inclusion criteria included age 18-75 years, Eastern Cooperative Oncology Group performance status of 0-1, adequate bone marrow function (white blood cell count > 3000 cells/mm 3 , platelet count > 120 000 cells/mm 3 ), adequate renal function (blood urea nitrogen < 25 mg/dL, creatinine < 1.5 mg/dL) and normal liver function (bilirubin < 2 mg/dL). Exclusion criteria were previous or concurrent malignancy at other sites, with the exception of basal or squamous cell carcinoma of the skin, and uncontrolled severe infection and/or medical problems unrelated to malignancy which would limit full compliance with the study. The trial was approved by the local ethics committee and Institutional Review Board, and all patients gave written informed consent agreeing to undergo all the procedures described and to their data being collected.
Pretreatment work-up included clinical examination, pelvic and rectovaginal examination under anesthesia, chest radiography, complete blood count and measurement of liver and renal function. Transabdominal and transvaginal ultrasound examination, abdominopelvic MRI and PET/CT scan were carried out in order to exclude cases with distant sites of disease; cystoscopy and proctoscopy were performed only in case of clinical suspicion of bladder and/or rectal invasion. After completion of the staging work-up, all imaging examinations were discussed by the tumor board (including gynecological oncologists, ultrasound examiners, radiologists, nuclear physicians, radiotherapists and oncological surgeons) and compared with the findings of the clinical examination, and a consensus reached on the FIGO staging for each patient. Regardless of the FIGO stage, which is based on only clinical evaluation, when there was disagreement regarding parametrial infiltration, MRI was considered superior to clinical examination and transvaginal examination. MRI was chosen because, in our research protocol, we aimed to evaluate early and final responses to treatment compared with the baseline condition, which is not feasible using clinical evaluation only and requires imaging. Moreover, MRI is generally considered the imaging method of choice to guide treatment options 29 . When there was disagreement regarding metastatic lymph nodes, PET/CT scan was considered superior to MRI and ultrasound examination.
Chemoradiation therapy
Neoadjuvant chemoradiation therapy included conformal irradiation of the pelvic lymph node, bulky tumor, parametria and upper part of the vagina, with a total dose of 39.6 Gy (1.8 cGy/fraction, 22 fractions), plus additional irradiation of primary tumor and parametria with 10.8 Gy administered with concomitant boosts (0.9 cGy/fraction, 12 fractions every other day) 18 . Concomitant chemotherapy included cisplatin (20 mg/m 2 , 2-h intravenous infusion) during the first and last 4 days of treatment and capecitabine (1300 mg/m 2 /day, orally) during the first 2 weeks and last 2 weeks of treatment.
Ultrasound examination
All ultrasound examinations were performed by the same examiner (A.C.T.) skilled in gynecological oncology and with more than 15 years of experience in gynecological ultrasound. The women were examined in the lithotomy position with an empty bladder. A transabdominal scan was performed in order to detect iliac and paraaortic lymph nodes and hydronephrosis. A predefined transvaginal examination protocol was carried out for each patient, including 2D grayscale and power/color Doppler examination, 3D grayscale and power Doppler evaluation and contrast-enhanced ultrasound examination with infusion of SonoVue contrast agent (Bracco Imaging S.p.A, Milan, Italy). All 2D and 3D scans were performed using a GE Voluson E8 (GE Medical Systems, Zipf, Austria) ultrasound machine equipped with a multifrequency 5-9-MHz endovaginal transducer and a 3-or 3.5-5.0-MHz convex transducer for the grayscale exams. Contrast-enhanced ultrasound examinations were performed using a MyLab 70 XVG (Esaote, Genova, Italy) machine, with a 5-9-MHz transducer equipped with dedicated software for ultrasound contrast.
A previously described standardized examination technique was used in all patients 6 . Briefly, cervical cancer was identified as a solid mass, with irregular border and disruption of the cervical canal. The tumor was measured in three dimensions (anteroposterior and craniocaudal diameters were obtained in the sagittal plane and laterolateral diameter in the transverse plane of the cervix). The maximum diameters were used to calculate the tumor volume by the ellipsoid formula (anteroposterior × craniocaudal × laterolateral diameter × π/6). Echogenicity of the tumor and parametrial infiltration were described as previously reported by Testa et al. 5 and Epstein et al. 30 . In particular, the echogenicity of the tumor was defined as hypoechoic, isoechoic or hyperechoic, in comparison with the surrounding cervical stroma. Infiltration of the parametria was defined as irregular extension of hypoechogenic prominences into the pericervical tissue.
To assess intratumoral blood flow, power Doppler settings were set to achieve maximum sensitivity to detect low-velocity flow without noise (frequency, 5 MHz; power Doppler gain, 0.8-2.0; pulse repetition frequency, 0.6 KHz). A subjective semiquantitative assessment of the amount of detectable blood flow was made using the color score described by Timmerman et al. 31 (1 = no vascularization; 2 = minimal vascularization; 3 = moderate vascularization; 4 = high vascularization).
3D grayscale ultrasound volumes were acquired using the maximum volume box (120
• ) and an image angle large enough to include the uterine cervix, the bladder and the rectum. The lowest sweep velocity was used to obtain maximum image quality. 3D power Doppler volumes were acquired using a volume box of 120
• , a pulse repetition frequency of 0.6 KHz and an image angle including the cervix and pericervical tissues. The volume was acquired during a time interval varying from 10 to 20 s, while the patient remained as still as possible. Volume acquisition was repeated if there were flash-type artifacts due to respiratory or bowel movements. The volumes were stored and evaluated offline. Using 4DView software (GE Medical Systems) and Virtual Organ Computer-aided AnaLysis (VOCAL™) with the rotational technique and rotation step of 15
• , the cervical tumor was outlined in Plane A, and the 3D tumor volume was calculated. 3D power Doppler indices (vascularization index (VI), flow index (FI) and vascularization flow index (VFI)) were calculated automatically ( Figure 1 ).
The VI (expressed as percentage) reflects the number of vessels within the volume of interest. FI (expressed as a number ranging from 0 to 100) is the average color value of all color voxels, representing the average color intensity. VFI (expressed as a number ranging from 0 to 100) is a simple mathematical formula obtained from VI and FI (VI × FI/100) and reflects both blood flow and vascularization 32, 33 . All 3D tumor volumes were analyzed twice by a single operator (M.C.M.) with more than 10 years of experience in gynecological ultrasound. During the second analysis, the operator was blinded to the findings of the first. As the estimated intraobserver reproducibility was good (no significant difference was observed between pairs of measurements, P = 0.279 for VI, P = 0.097 for FI, P = 0.198 for VFI and P = 0.588 for tumor volume), the first measurement was used for the analysis.
After 2D and 3D ultrasound examination, a contrast-enhanced ultrasound examination was performed using CnTI™ (contrast-tuned imaging) technology (Esaote) integral to the transvaginal probe and with the ultrasound contrast agent SonoVue (Bracco Imaging SpA, Milan, Italy). The same settings were used for all contrast examinations (pulse repetition frequency, 750 Hz; frequency = penetration; derated pressure, 126 kPa; focus position immediately beneath the lesion; general gain, 150). The contrast medium was injected intravenously into a superior peripheral vein (e.g. antecubital, dorsal, wrist or hand vein) as a 2.4-mL bolus over approximately 2 s using a 20-gauge catheter under aseptic conditions. At each examination, the patient was administered a maximum of two injections (i.e. a maximum of 4.8 mL SonoVue in total). The first injection was used to analyze the dynamic profile of the contrast ('curve wash-in/wash-out') during the passage of contrast through the largest longitudinal section of the tumor. A 3-min CnTI recording for time-intensity analysis was started immediately after completion of the SonoVue bolus injection. The examiner did not move the probe during the 3-min recording. The second injection was carried out in case of technical problems with the first bolus (e.g. malfunction of the ultrasound equipment, incorrect positioning of the needle) with a minimum interval elapsed between first and second administrations of SonoVue of 20 min in order to allow clearance of contrast from the tumor under study. All contrast videoclips were stored electronically for later analysis using dedicated software. The safety of SonoVue was evaluated through physical examination, monitoring of vital signs, monitoring for adverse event at the time of injection and monitoring for other adverse events within 30 min of each administration of SonoVue. This temporal The latter shows region of interest (ROI) (outlined in green) on both contrast-enhancement (d1) and color-coded profile (d2), as well as time-intensity curve (d3), with table showing peak enhancement value obtained from ROI analysis.
window was considered appropriate to capture any event related to the study drug, considering the short half-life of SonoVue (12 min) and that more than 80% of sulfur hexafluoride administered would have been released in exhaled air within 2 min after administration, with about 100% being eliminated by 15 min.
The software package VueBox ® (vuebox.bracco .ch/php/Support.php, Bracco Imaging S.p.A) was used for quantification of contrast perfusion. This software processes the signal intensity changes over time induced in an organ or lesion by the intravenous injection of SonoVue. On CnTI examination, the highest value of signal intensity (100%) corresponds to white in the grayscale bar of the ultrasound image and the lowest value (0%) corresponds to black in the grayscale bar. As a result of the processing of contrast signals, the software provides pixel-by-pixel color-coded maps of the perfusion parameter for the lesion under investigation. High values of the perfusion parameter are coded in red (the darker the red the higher the intensity), low values are coded in blue (the darker the blue the lower the intensity) and intermediate intensities are coded in yellow (the darker the yellow the higher the intensity).
The bolus model considering the wash-in/wash-out kinetics was used for the analysis. Perfusion parameters, such as wash-in rate (WiR: sharpness of the signal intensity), peak enhancement (PE: maximum signal intensity during the transit of contrast), rise time (RT: time that a contrast echo signal takes to go from baseline level to PE) and area under the time-intensity curves during wash-in and wash-out were calculated in a specific region of interest (ROI) corresponding to the lesion. All ROIs were identified and analyzed by a single operator (T.P.) (Figure 1 ).
Assessment of clinical response, surgery and histopathological evaluation
Response to treatment was evaluated objectively 4-6 weeks after completion of chemoradiation according to Response Evaluation Criteria for Solid Tumors (RECIST) criteria 34 . Both patients achieving complete response and those achieving partial response to treatment, according to the RECIST criteria, underwent triage for radical hysterectomy according to the classification of Querleu and Morrow 35 , and pelvic, with or without aortic, lymphadenectomy within 6-8 weeks from completion of chemoradiation. Aortic lymphadenectomy was performed in case of: (1) positive pelvic lymph nodes on frozen-section analysis, performed routinely during surgery; (2) positive pelvic lymph nodes on imaging at initial staging work-up; and (3) suspicious aortic lymph nodes assessed intraoperatively. Patients who experienced no change or who experienced progression of the disease were treated with salvage chemotherapy.
All imaging methods (ultrasound, MRI and PET/CT scan) were evaluated using histology as the reference standard. Histopathological evaluation corresponded to the standard procedures performed in our institution: the cervix was sectioned clockwise in at least 12 blocks, and embedded entirely in paraffin. From each block, two slides, 3-to 4-μm thick, were cut at different levels and stained with hematoxylin and eosin. When appropriate, additional sections were prepared for specific immunohistochemistry tests 36 . The residual disease at any site was expressed as length in millimeters, and response was defined, according to the TNM classification 36 , as: complete (absence of any residual tumor after treatment at any site level (pR0)); or partial, either microscopic (persistent tumor foci < 3 mm in maximum dimension (pR1)) or macroscopic (persistent tumor foci ≥ 3 mm in maximum dimension (pR2)) residual tumor at histopathological examination. Adjuvant treatment with a platinum-taxane combination was administered in case of pathological involvement of vaginal margins and/or lymph nodes and/or presence of lymph-vascular-space invasion.
Statistical analysis
In the literature there are very few data regarding the accuracy of MRI, PET/CT and ultrasound in predicting pathological response to chemoradiation in patients with locally advanced cervical cancer and those available come from retrospective studies on small series of patients. Therefore, the sample size was calculated on the basis of the results described in Testa et al. 6 , according to Simon's design, in order to detect a 15% difference in the accuracy of MRI; considering that MRI diagnostic accuracy = 75% (p0), an α type-1 error = 0.01, and a β type-II error = 0.1 (power, 90%), a total of 86 patients would be required. Taking into account a dropout rate of around 10%, a final sample size of at least 95 patients was planned.
For the analysis, patients were divided in two groups according to their pathological response: those with a complete response and those with a partial response. We analyzed ultrasound parameters obtained at both baseline and early examination, after 2 weeks of neoadjuvant treatment. For each patient, we also calculated the change in quantitative variables from baseline to early examination in terms of percentage difference, using the formula: % difference = 100 × ((baseline value − early value)/baseline value).
Results are presented as percentage for nominal variables and as median (range) for continuous variables. Comparisons between the two groups were made with Wilcoxon's rank-sum non-parametric test or the Mann-Whitney U-test for continuous variables and χ 2 -test for nominal variables, as appropriate.
ROC curves were generated for statistically significant ultrasound variables on univariate analysis to evaluate their diagnostic ability to predict partial pathological response. The ROC curves were also used to determine mathematically the best cut-off value to predict partial responders vs complete responders, defined as that corresponding to the point on the ROC curve situated farthest from the reference line. For each diagnostic test and for each corresponding best cut-off value, the accuracy, sensitivity, specificity, positive and negative likelihood ratios (LR+ and LR−) and the numbers of true positive, true negative, false positive and false negative values were also calculated. The statistical calculations were performed using the Statistical Package for the Social Sciences software (SPSS version 20.0, SPSS Statistics, IBM Corp., Armonk, NY, USA), except for the ROC curve analysis, which was assessed using the pROC package in R software (R version 3.3.1, https://cran.r-project.org/). Two-sided tests were used and the significance level was set at P < 0.05. Figure 2 shows the consolidated standards for reporting trial (CONSORT) diagram for our study population: between October 2010 and June 2014, we enrolled into the study 108 patients who were eligible candidates to undergo neoadjuvant chemoradiation; of those, 20 were excluded (16 declined the early evaluation, two died and two experienced disease progression). Eighty-eight patients completed neoadjuvant treatment and underwent radical hysterectomy. Complete or partial (microscopic or macroscopic) pathological response to treatment was documented in 40 (45.5%) and 48 (54.5% (microscopic 23.8% and macroscopic 30.7%)) patients, respectively. There were no patients with no change and none with progression of the disease.
RESULTS
Clinical and pathological features of the study population are summarized in IIIA and 10.2% (9/88) were Stage IIIB, with no statistically significant difference in staging between the group with complete and that with partial pathological response. At staging work-up, pelvic lymph node involvement was documented in 40 (45.5%) patients, with no statistically significant difference between the two groups. There were no statistically significant differences in the distribution of pathological response to treatment according to stage of disease; in particular, the rates of complete and partial pathological response were 45% and 55%, respectively, in Stage IB-IIB patients compared with 46% and 54%, respectively, in Stage IIIA-IIIB patients (data not shown). There was a statistically significantly higher prevalence of undifferentiated tumors (G3) in the partial-response group compared with the complete-response group (P = 0.026).
Baseline ultrasound examination
The ultrasound findings before treatment (baseline examination) are shown in Table 2 , according to pathological response. The 2D grayscale ultrasound parameters, including tumor volume and tumor diameters, did not differ significantly before treatment between patients who went on to have a complete and those who had a partial response. The distribution of baseline color score according to pathological response differed, with higher prevalence of color score 4 in patients with a complete response vs those with a partial response (52.5% vs 31.3%, P = 0.01).
Of the 3D vascular indices, the VI and VFI were significantly lower in patients who went on to have a partial response than those who had a complete response (P = 0.037 and P = 0.036, respectively).
The contrast-enhanced examination was available in 86 of the 88 patients and perfusion was detected in all of them (Table 2 ). In the ROI analysis, tumor PE and tumor WiR values were lower in the partial-response group than in the complete-response group (P = 0.006 and P = 0.003, respectively) and the tumor RT was longer (P = 0.038). Neither the difference in tumor wash-in, nor that in tumor wash-out, between the two groups was statistically significant (P = 0.186 and P = 0.103, respectively). Representative ultrasound and contrast-enhanced images at baseline examinations in a case with complete and one with partial response to neoadjuvant chemoradiation are shown in Figures 3 and 4 .
Early ultrasound examination
The ultrasound findings after 2 weeks of treatment (early examination) are shown in Table 2 , according to pathological response. Both maximum tumor diameter and tumor volume were significantly higher in patients with a partial pathological response than in those with a complete pathological response (P = 0.006 and P = 0.019, respectively), while there was no statistically significant difference in terms of color score between the two groups.
Regarding the 3D vascular indices, after 2 weeks of treatment, the VI remained significantly lower in , respectively, and after 2 weeks of treatment were 37 mm (d) and 13.73 cm 3 (e). Vascularization index was 60.6% at baseline (b) and 60.2% after 2 weeks of treatment (e). Peak-enhancement value was 14 760 auxiliary units (a.u.) before treatment and 17 289 a.u. after 2 weeks of treatment. ROI, region of interest.
patients with a partial response than in those with a complete response (P = 0.024), whereas there were no statistically significant differences in terms of FI and VFI between the two groups. The contrast examination was available in 87 of the 88 patients and perfusion was detected in all of them. In contrast to the results obtained on ROI analysis at baseline examination, there were no statistically significant differences in any of the contrast parameters between the two groups.
Representative ultrasound and contrast-enhanced images at the early examination in a case with complete and one with partial response to neoadjuvant chemoradiation are shown in Figures 3 and 4 . Percentage difference = 100 × (baseline value − early value)/baseline value. *Partial response vs complete response, P < 0.05 considered statistically significant. †Available for 69 patients. ‡Available for 85 patients. a.u., auxiliary units; 3D, three-dimensional; FI, flow index; VFI, vascularization flow index; VI, vascularization index. Table 3 compares percentage differences of ultrasound parameters, i.e. percentage change in values obtained at early examination relative to those at baseline, between complete and partial responders. Percentage reduction in tumor volume after 2 weeks of treatment was significantly less in the partial-response group (16.4%) than in the complete-response group (55.2%) (P = 0.017), as was the percentage reduction in maximum tumor diameter (8.7% vs 20.8%) (P = 0.012). Percentage change in VI and VFI were not significantly different between the two groups. In the contrast analysis, percentage change in tumor PE and tumor WiR were significantly lower in the partial-response group than in the complete-response group (P = 0.031 and P = 0.015, respectively).
Percentage difference in complete and partial responders
Comparison of tumor volume, VI and tumor PE between baseline and early examinations in both completeand partial-response groups are shown in Figure 5 .
ROC curve analysis
The quality of the most significant diagnostic parameters in predicting partial pathological response is shown in Table 4 . The following baseline variables predicted partial pathological response: VI, VFI, tumor PE, tumor RT and tumor WiR. The following variables investigated after 2 weeks of neoadjuvant therapy predicted partial pathological response: tumor volume, tumor maximum diameter and VI. Moreover, percentage difference in tumor volume, maximum diameter, tumor PE and tumor WiR, 2 weeks after treatment, predicted partial pathological response. The best cut-off values of these variables, and their corresponding sensitivity, specificity, LR+ and LR-, are shown in Table 4 .
DISCUSSION
This large single-center study evaluated the performance of ultrasound and contrast parameters in predicting partial pathological response after 2 weeks of neoadjuvant treatment in patients with locally advanced cervical cancer.
We found that several ultrasound parameters evaluated before treatment differed between patients who went on to have a partial response to treatment and those who had a complete response. In particular, at baseline examination, the cervical lesions which had a partial response were less vascularized than were those with a complete response, with lower VI and VFI at 3D ultrasound, and lower PE and WiR and longer RT at contrast-enhanced ultrasound examination. At the examination performed after 2 weeks of neoadjuvant treatment, no 3D or contrast parameter, with the exception of VI at 3D ultrasound, differed between the two groups. Moreover, 2D tumor size, which was similar at the baseline examination between patients who went on to have partial and those with complete pathological response, differed significantly after 2 weeks of treatment, with a smaller reduction in size in those with partial response. However, neither ultrasound parameters obtained before treatment nor those assessed 2 weeks after treatment had cut-off values with acceptable accuracy, sensitivity and specificity for discriminating pathological response to neoadjuvant therapy.
The strength of our study is the large number of cases examined in a single center following a standardized protocol, with complete data available in almost all cases. It is worth noting that a potential limitation of the study analysis is that patients with microscopic and those with macroscopic residual disease were grouped together in the partial-response group, due to our study sample size.
There have been various studies investigating ultrasound parameters in patients with locally advanced cervical cancer (Table 5) . Some, comparing sonographic and MRI evaluation in assessing the presence and extent of disease, included both patients with early-stage disease undergoing primary surgery and those with locally advanced cervical cancer undergoing neoadjuvant treatment 6, 7 . In all previous studies, the ultrasound scan was performed only before or only after treatment 6, 24, 25, 37, 38 . In contrast, in the present study we analyzed ultrasound parameters only in patients undergoing neoadjuvant chemoradiation and we performed the examinations before, after and during treatment. Furthermore, while some previous studies assessed the performance of ultrasound in predicting tumor response, including tumor volume and vascular indices, to chemo-or chemoradiation therapy 26, [39] [40] [41] [42] [43] , their results were controversial. Some of them analyzed a very small sample size 40 ; others assessed only the clinical response without investigating the pathological data 26, 41 ; and others included patients treated with neoadjuvant chemotherapy rather than chemoradiation 39, 42, 43 . Although our findings could be of interest scientifically, the interpretation and application of these results in clinical practice may be limited. The early examination can help to discriminate promptly those patients who will undergo only a partial response, as they have a greater tumor volume compared with those who will experience a complete response. However, this early examination does not seem to contribute much additional predictive value to the baseline investigation as far as contrast data are concerned. Indeed, contrast parameters that differed at baseline between the two groups (with lower peak in patients with partial response) were similar at the early examination. These results seem to confirm that contrast evaluation of the irradiated cervix is non-specific, as contrast uptake may occur both in residual tumor and in post-treatment normal tissue. This was also confirmed in a small series by Csutak et al. 25 , in which ultrasound assessment with contrast agents after treatment did not appear to be useful in predicting pathological response.
The only parameter that differed significantly between our two groups at both baseline and early examinations was VI, which was higher in patients who went on to have a complete response compared with those who had a partial response. This 3D-ultrasound parameter correlates with the number of color-coded voxels, as well as with the number of erythrocytes, reflecting the concentration of intratumoral oxygen 44, 45 . As recent studies have proved that tumor hypoxia makes solid tumors resistant to standard therapy [46] [47] [48] [49] , our findings suggest that VI may be a useful parameter that is able to discriminate those patients who will have a poor response to neoadjuvant treatment.
The availability of markers able to predict at an early stage in treatment the pathological response would have important clinical implications and advantages.
Conventionally, tumor response to therapy is assessed by changes in tumor size according to RECIST using CT scan or MRI. Unfortunately, such information from post-therapy imaging after completion of treatment usually comes too late to impact realistically on patient management. If failure of therapy could be predicted effectively as early as possible in the initial course of treatment, it would perhaps provide a window of opportunity to change the initial therapy up-front, as well as to adjust the clinical management 49 .
In conclusion, both baseline ultrasound examination and that performed 2 weeks after initiation of treatment show differences in morphological and vascularized parameters between patients with complete and those with partial response to neoadjuvant chemoradiation. However, neither ultrasound parameters obtained before treatment nor those performed after 2 weeks of treatment had cut-off values with acceptable accuracy, sensitivity and specificity for predicting pathological non-complete response to neoadjuvant therapy. Larger series, new ultrasound parameters and different timing of ultrasound examinations during neoadjuvant treatment could be investigated further, to identify markers able to predict the pathological response to neoadjuvant treatment in patients with locally advanced cervical cancer.
